InvestSMART

Dimerix Limited (ASX:DXB)

ALERT: Price-sensitive ASX Announcement for DXB
Current share price for DXB : $0.310 0.07 (29.17%)+
Announcement
Release
17 Jul 2026 9:03AM
Price at Release
$0.240
Full Release
download
Summary
Dimerix Limited has expanded its pipeline by acquiring the Phase 2-ready asset DMX-652 from Mission Therapeutics. DMX-652, a selective inhibitor of the mitochondrial enzyme USP30, is designed to address acute kidney injury (AKI) and aligns with Dimerix's strategy to focus on rare kidney diseases with unmet medical needs. The acquisition includes patent rights and an open US IND with an FDA-approved Phase 2 trial protocol. The move leverages Dimerix's expertise in renal diseases, complements its existing Phase 3 program for FSGS, and anticipates a significant market opportunity due to the lack of approved AKI therapies. Funding from current reserves and partnerships supports this strategic expansion.
Key Points
  • Dimerix Limited acquires Phase 2-ready asset DMX-652 from Mission Therapeutics to expand its pipeline in kidney diseases.
  • DMX-652 is a selective inhibitor targeting mitochondrial enzyme USP30, initially focusing on acute kidney injury (AKI).
  • Phase 1 trials demonstrated DMX-652's safety and pharmacokinetic profile, with potential for Phase 2 clinical trials.
  • The acquisition aligns with Dimerix's strategy to build a focused pipeline for rare kidney diseases with unmet medical needs.
  • DMX-652 acquisition includes patent rights and an open US IND with a Phase 2 trial protocol approved by FDA.
  • There are no approved therapies for AKI, which presents a significant unmet medical need and market opportunity.
  • Funding through existing cash reserves and agreements with partners supports the development pipeline.
  • DMX-652 and DMX-200 together form a comprehensive renal pipeline, addressing both acute and chronic kidney disease.
IMPORTANT NOTE: This information is autogenerated and has not been reviewed for accuracy or completeness. You should refer to the full announcement here for further information.